Pulmonary Complications of Polymyositis and Dermatomyositis

ABSTRACT

Polymyositis and dermatomyositis are systemic inflammatory diseases with unknown etiology and prognosis. Pulmonary involvement is increasingly recognized to be a major complication and a common cause of morbidity and mortality in these diseases. Thus a thorough pulmonary evaluation is necessary to permit appropriate management. There are three categories of pulmonary complications in myositis: aspiration pneumonia, hypoventilation, and interstitial lung disease (ILD). ILD is a frequent pulmonary complication in patients with myositis, and respiratory symptoms are not reliable signs for diagnosis. The strongest predictive factor for ILD in patients with myositis is the presence of antihistidyl transfer ribonucleic acid (tRNA) synthetase antibodies (anti-Jo-1), but ILD may also be present in patients without these autoantibodies. Therefore, all patients with polymyositis or dermatomyositis should be investigated with chest radiography, high-resolution computed tomography, and lung function tests.

KEYWORDS

Polymyositis - dermatomyositis - interstitial lung disease

REFERENCES

• 1 Dalakas M C. Polymyositis, dermatomyositis and inclusion-body myositis.  N Engl J Med. 1991;  325 1487-1498
• 2 Plotz P H, Rider L G, Targoff I N, Raben N, O'Hanlon T P, Miller F W. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy.  Ann Intern Med. 1995;  122 715-724
• 3 Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden.  Scand J Rheumatol. 1997;  26 104-106
• 4 Hengstman G J, van Venrooij W J, Vencovsky J, Moutsopoulos H M, van Engelen B G. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient.  Ann Rheum Dis. 2000;  59 141-142
• 5 Oddis C V, Conte C G, Steen V D, Medsger Jr T A. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982.  J Rheumatol. 1990;  17 1329-1334
• 6 Kaipiainen-Seppanen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland.  J Intern Med. 1996;  240 81-84
• 7 Medsger Jr T A, Robinson H, Masi A T. Factors affecting survivorship in polymyositis: a life-table study of 124 patients.  Arthritis Rheum. 1971;  14 249-258
• 8 Hochberg M C. Epidemiology of polymyositis/dermatomyositis.  Mt Sinai J Med. 1988;  55 447-452
• 9 Arahata K, Engel A G. Monoclonal antibody analysis of mononuclear cells in myopathies, I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.  Ann Neurol. 1984;  16 193-208
• 10 Engel A G, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies, II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis.  Ann Neurol. 1984;  16 209-215
• 11 Nyberg P, Wikman A L, Nennesmo I, Lundberg I. Increased expression of interleukin 1 alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis.  J Rheumatol. 2000;  27 940-948
• 12 Love L A, Leff R L, Fraser D D et al.. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.  Medicine (Baltimore). 1991;  70 360-374
• 13 Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar C P, Martínez-Gómez X, Vilardell-Tarrés X. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy.  Arthritis Rheum. 2006;  55 791-798
• 14 Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller F W et al.. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies.  Arthritis Rheum. 1997;  40 1257-1266
• 15 Rutjes S A, Vree Egberts W T, Jongen P, Van Den Hoogen F, Pruijn G J, Van Venrooij W J. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy.  Clin Exp Immunol. 1997;  109 32-40
• 16 Lundberg I, Ulfgren A K, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.  Arthritis Rheum. 1997;  40 865-874
• 17 Tateyama M, Nagano I, Yoshioka M, Chida K, Nakamura S, Itoyama Y. Expression of tumor necrosis factor-alpha in muscles of polymyositis.  J Neurol Sci. 1997;  146 45-51
• 18 Ulfgren A K, Grundtman C, Borg K et al.. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids.  Arthritis Rheum. 2004;  50 1586-1594
• 19 Fox S A, Ward B K, Robbins P D, Mastaglia F L, Swanson N R. Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction.  Muscle Nerve. 1996;  19 23-28
• 20 Leff R L, Love L A, Miller F W et al.. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle.  Lancet. 1992;  339 1192-1195
• 21 Friedman J M, Pachman L M, Maryjowski M L et al.. Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies.  Arthritis Rheum. 1983;  26 214-216
• 22 O`Hanlon T P, Carrick D M, Arnett F C et al.. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -DRB1 allelic profiles and motifs define clinicopathologic groups in Caucasians.  Medicine. 2005;  84 338-349
• 23 Chinoy H, Salway F, Fertig N The UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC) et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype.  Arthritis Res Ther. 2006;  8 R13
• 24 Bohan A, Peter J B. Polymyositis and dermatomyositis.  N Engl J Med. 1975;  292 344-347
• 25 Bohan A, Peter J B. Polymyositis and dermatomyositis.  N Engl J Med. 1975;  292 403-407
• 26 Targoff I N, Miller F W, Medsger Jr T A, Oddis C V. Classification criteria for the idiopathic inflammatory myopathies.  Curr Opin Rheumatol. 1997;  9 527-535
• 27 Hoogendijk J E, Amato A A, Lecky B R et al.. 119th ENMC International Workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis 10-12 October 2003, Naarden, the Netherlands.  Neuromuscul Disord. 2004;  14 337-345
• 28 Tanimoto K, Nakano K, Kano S et al.. Classification criteria for polymyositis and dermatomyositis.  J Rheumatol. 1995;  22 668-674
• 29 Marie I, Hachulla E, Cherin P et al.. Interstitial lung disease in polymyositis and dermatomyositis.  Arthritis Rheum. 2002;  47 614-622
• 30 Marie I, Hachulla E, Cherin P et al.. Opportunistic infections in polymyositis and dermatomyositis.  Arthritis Rheum. 2005;  53 155-165
• 31 Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.  Medicine. 2004;  83 35-42
• 32 Hepper N G, Ferguson R H, Howard Jr F M. Three types of pulmonary involvement in polymyositis.  Med Clin North Am. 1964;  48 1031-1042
• 33 Dickey B F, Myers A R. Pulmonary disease in polymyositis/dermatomyositis.  Semin Arthritis Rheum. 1984;  14 60-76
• 34 Braun N M, Arora N S, Rochester D F. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies.  Thorax. 1983;  38 616-623
• 35 Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis: a computer-assisted analysis of ninety-two cases.  Arthritis Rheum. 1985;  28 249-255
• 36 Schwarz M I. The lung in polymyositis.  Clin Chest Med. 1998;  19 701-712 , viii.
• 37 Takizawa H, Shiga J, Moroi Y et al.. Interstitial lung disease in dermatomyositis: clinicopathological study.  J Rheumatol. 1987;  14 102-107
• 38 Fathi M, Dastmalchi M, Rasmussen E, Lundberg I E, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis.  Ann Rheum Dis. 2004;  63 297-301
• 39 Wallaert B, Hatron P Y, Grosbois J M, Tonnel A B, Devulder B, Voisin C. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage: relationship between alveolitis and subsequent changes in lung function.  Am Rev Respir Dis. 1986;  133 574-580
• 40 Remy-Jardin M, Giraud F, Remy J, Copin M C, Gosselin B, Duhamel A. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation.  Radiology. 1993;  189 693-698
• 41 Aoun N Y, Velez E, Aggarwal A, Hayes G B, Kenney L A. Fatal acute interstitial pneumonitis complicating polymyositis in a 41-year-old man.  Respir Care. 2004;  49 1515-1521
• 42 Friedman A W, Targoff I N, Amett F C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis.  Semin Arthritis Rheum. 1996;  26 459-467
• 43 Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with polymyositis/dermatomyositis.  Intern Med. 2002;  41 1135-1141
• 44 Schnabel A, Reuter M, Biederer J, Richter C, Gross W L. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.  Semin Arthritis Rheum. 2003;  32 273-284
• 45 Suda T, Fujisawa T, Enomoto N et al.. Interstitial lung diseases associated with amyopathic dermatomyositis.  Eur Respir J. 2006;  28 1005-1012
• 46 Sakamoto N, Mukae H, Fujii T et al.. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis.  Intern Med. 2004;  43 838-842
• 47 High W A, Cohen J B, Murphy B A, Costner M I. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis.  J Am Acad Dermatol. 2003;  49 295-298
• 48 Frazier A R, Miller R D. Interstitial pneumonitis in association with polymyositis and dermatomyositis.  Chest. 1974;  65 403-407
• 49 Muller N L, Staples C A, Miller R R, Vedal S, Thurlbeck W M, Ostrow D N. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation.  Radiology. 1987;  165 731-734
• 50 Muller N L, Miller R R, Webb W R, Evans K G, Ostrow D N. Fibrosing alveolitis: CT-pathologic correlation.  Radiology. 1986;  160 585-588
• 51 Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings.  Radiology. 1992;  184 779-785
• 52 Lee C S, Chen T L, Tzen C Y et al.. Idiopathic inflammatory myopathy with diffuse alveolar damage.  Clin Rheumatol. 2002;  21 391-396
• 53 Bonnefoy O, Ferretti G, Calaque O et al.. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis.  Eur J Radiol. 2004;  49 235-244
• 54 Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT.  AJR Am J Roentgenol. 1997;  169 83-87
• 55 Arakawa H, Yamada H, Kurihara Y et al.. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation.  Chest. 2003;  123 1096-1103
• 56 Douglas W W, Tazelaar H D, Hartman T E et al.. Polymyositis-dermatomyositis-associated interstitial lung disease.  Am J Respir Crit Care Med. 2001;  164 1182-1185
• 57 Tazelaar H D, Viggiano R W, Pickersgill J, Colby T V. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings.  Am Rev Respir Dis. 1990;  141 727-733
• 58 Wells A U, Hansell D M, Corrin B et al.. High-resolution computed tomography as a predictor of lung histology in systemic sclerosis.  Thorax. 1992;  47 738-742
• 59 Tansey D, Wells A U, Colby T V et al.. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis.  Histopathology. 2004;  44 585-596
• 60 Kubo M, Ihn H, Yamane K et al.. Serum KL-6 in adult patients with polymyositis and dermatomyositis.  Rheumatology (Oxford). 2000;  39 632-636
• 61 Bandoh S, Fujita J, Ohtsuki Y et al.. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.  Ann Rheum Dis. 2000;  59 257-262
• 62 Ihn H, Asano Y, Kubo M et al.. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.  Rheumatology (Oxford). 2002;  41 1268-1272
• 63 Fujita J, Dobashi N, Tokuda M et al.. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/dermatomyositis.  J Rheumatol. 1999;  26 2377-2382
• 64 Fujisawa T, Suda T, Nakamura Y et al.. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.  J Rheumatol. 2005;  32 58-64
• 65 Marguerie C, Bunn C C, Beynon H L et al.. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.  Q J Med. 1990;  77 1019-1038
• 66 Spath M, Schroder M, Schlotter-Weigel B et al.. The long-term outcome of anti-Jo-1-positive inflammatory myopathies.  J Neurol. 2004;  251 859-864
• 67 Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody.  Intern Med. 2002;  41 584-588
• 68 Tubery M, Lauque D, Murris M et al.. Course of interstitial lung diseases associated with inflammatory myopathies: apropos of 5 cases.  Ann Med Interne (Paris). 1997;  148 2-10
• 69 Tomsic M, Sifrer F. Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody.  Wien Klin Wochenschr. 2000;  112 728-731
• 70 Miyake S, Ohtani Y, Sawada M et al.. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 128-133
• 71 Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X et al.. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients.  Lupus. 2005;  14 534-542
• 72 Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants.  Autoimmunity. 2005;  38 383-392
• 73 Wilkes M R, Sereika S M, Fertig N, Lucas M R, Oddis C V. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.  Arthritis Rheum. 2005;  52 2439-2446
• 74 Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up.  Rheumatology (Oxford). 2004;  43 531-532
• 75 Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications.  Semin Arthritis Rheum. 2006;  36 144-152
• 76 Hengstman G J, van den Hoogen F H, van Engelen B G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.  Eur Neurol. 2004;  52 61-63